Image source: Shutterstock
Highlights
Microba announces AUD 6.04 million raised in first tranche of private placement, with shares priced at AUD 0.09.
Second tranche and Share Purchase Plan (SPP) to bring total capital raise to over AUD 14 million.
Funds will support expansion in Australia and the UK, product development, and commercial operations.
Microba Life Sciences Ltd (ASX:MAP), a precision microbiome company focused on developing therapeutics for chronic diseases, has announced a significant capital raise to accelerate its commercial and clinical operations in Australia and the United Kingdom.
In a filing dated 23 June 2025, Microba revealed it has secured AUD 6.04 million through a first tranche private placement, issuing 67,177,796 new shares at AUD 0.09 per share. The offering attracted interest from existing and new investors, including Sonic Healthcare Ltd, which will participate in the placement.
Alongside the first tranche, Microba also announced a second tranche private placement to raise a further AUD 6.45 million, with an issuance of 71,711,093 new shares, also priced at AUD 0.09 per share. Additionally, the company has launched a Share Purchase Plan (SPP) targeting up to AUD 2 million from eligible shareholders.
In total, Microba is seeking to raise over AUD 14 million across all funding rounds. Canaccord Genuity Australia Ltd and Morgans Corporate Ltd are acting as financial advisors for the offering.
The proceeds from the capital raise will be directed toward several strategic initiatives. These include expanding clinical adoption of Microba’s core microbiome testing products, particularly in Australia and the UK, advancing the product development roadmap, and building scalable sales, marketing, and commercial operations in key markets.
The company also intends to use the funds to generate targeted clinical evidence to support regulatory and market acceptance of its products.
Microba, which operates in the emerging field of microbiome science, aims to use its proprietary platform to deliver personalised insights and therapeutic innovations. With chronic diseases continuing to pose a global health challenge, the company is positioning itself as a leader in microbiome diagnostics and clinical application.






Please wait processing your request...